公开(公告)号：US11524998B2

公开(公告)日：2022-12-13

申请号：US17375860

申请日：2021-07-14

Applicant: NOVARTIS AG

Inventor： Chad Eric Bigelow ,  Ana Maria Carrion ,  James Edgar Chastain ,  Kirk Lee Clark ,  Bijan Alexandre Etemad-Gilbertson ,  Joy Gispati Ghosh ,  Shawn Michael Hanks ,  Nicole Haubst ,  Ganesh Rajan Iyer ,  Nina Moker ,  Andrew Anh Nguyen ,  Stephen Hedrick Poor ,  Yubin Qiu ,  Nalini Velamur Rangaswamy ,  Michael Stefanidakis ,  Engin Toksoz ,  Michael Zbigniew Twarog

IPC: C07K16/22 ,  A61P27/02 ,  C07K16/46 ,  A61K39/00

Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

公开(公告)号：US09192663B2

公开(公告)日：2015-11-24

申请号：US13693330

申请日：2012-12-04

Applicant: NOVARTIS AG

Inventor： Winfried Elis ,  Seth Ettenberg ,  Andrew Paul Garner ,  Nicole Haubst ,  Xizhong Huang ,  Christian Carsten Silvester Kunz ,  Elizabeth Anne Reisinger Sprague ,  Qing Sheng

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/32 ,  A61K45/06 ,  A61K31/4439 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K31/4439 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).

Abstract translation: 本发明涉及与HER受体家族例如HER3受体相互作用的抗体或其片段。 特别地，其涉及识别包含来自结构域2和4的残基的HER3受体的构象表位的抗体或其片段，导致抑制配体依赖性和与配体无关的信号转导; 并允许配体结合（例如神经调节蛋白），同时防止配体诱导的信号转导活化。 这些抗体或片段可用于治疗以增加的HER3表达水平为特征的许多疾病或病症（例如食道癌）。 这些抗体或片段可用于治疗以减少组织重量（例如前列腺或子宫重量）或诱导组织萎缩（例如雄性乳房萎缩）为特征的抗体或片段能力的许多疾病或病症。

公开(公告)号：US10077317B2

公开(公告)日：2018-09-18

申请号：US14280017

申请日：2014-05-16

Applicant: Novartis AG

Inventor： Andrew Paul Garner ,  Elizabeth Anne Reisinger Sprague ,  Seth Alexander Ettenberg ,  Christian Kunz ,  Nicole Haubst ,  Winfried Elis

IPC: C07K16/30 ,  C07K16/32 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/32 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.

公开(公告)号：US10000561B2

公开(公告)日：2018-06-19

申请号：US15258683

申请日：2016-09-07

Applicant: NOVARTIS AG

Inventor： Matthew John Edwards ,  Jean-Michel Rene Rondeau ,  Danforth Miller ,  Daniel Huang ,  Hans-Peter Knopf ,  Gino Anselmus Van Heeke ,  Rene Hemmig ,  Kapil Gupta ,  Nicole Haubst ,  Barbara Andlauer

IPC: C07K16/24 ,  A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K45/06 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/1617 ,  A61K9/1623 ,  A61K2039/505 ,  A61K2039/544 ,  A61K2039/545 ,  A61P11/06 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

公开(公告)号：US10745473B2

公开(公告)日：2020-08-18

申请号：US15973735

申请日：2018-05-08

Applicant: NOVARTIS AG

Inventor： Matthew John Edwards ,  Jean-Michel Rene Rondeau ,  Danforth Miller ,  Daniel Huang ,  Hans-Peter Knopf ,  Gino Anselmus Van Heeke ,  Rene Hemmig ,  Kapil Gupta ,  Nicole Haubst ,  Barbara Andlauer

IPC: C07K16/24 ,  A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K9/16 ,  A61K39/00 ,  A61P37/08 ,  A61P11/06

Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

公开(公告)号：US10080800B2

公开(公告)日：2018-09-25

申请号：US14852003

申请日：2015-09-11

Applicant: NOVARTIS AG

Inventor： Winfried Elis ,  Seth Ettenberg ,  Andrew Paul Garner ,  Nicole Haubst ,  Xizhong Huang ,  Christian Carsten Silvester Kunz ,  Elizabeth Anne Reisinger Sprague ,  Qing Sheng

IPC: C07K16/00 ,  A61K39/395 ,  C12P21/08 ,  C07K16/32 ,  A61K45/06 ,  A61K31/4439 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K31/4439 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).